Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature (Q34997253)

5 August 2017

1 reference

title

Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature (English)

1 reference

5 August 2017

anti-retroviral agent

0 references

opportunistic infection

1 reference

1

Herminia Palacio

1 reference

5 August 2017

James G Kahn

2

1 reference

PubMed ID

12432135

5 August 2017

T Anne Richards

series ordinal

3

1 reference

PubMed ID

12432135

5 August 2017

Stephen F Morin

series ordinal

4

1 reference

5 August 2017

1 May 2002

1 reference

5 August 2017

Public Health Reports

1 reference

5 August 2017

117

1 reference

5 August 2017

3

1 reference

5 August 2017

233-51; discussion 231-2

1 reference

Racial disparity in influenza vaccination: does managed care narrow the gap between African Americans and whites?

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Racial differences in the use of invasive cardiovascular procedures: review of the literature and prescription for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Reducing racial disparities in transplant activation: whom should we target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Access to therapy in the Multicenter AIDS Cohort Study, 1989-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Racial differences in the use of drug therapy for HIV disease in an urban community

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Health services use by urban women with or at risk for HIV-1 infection: the HIV Epidemiology Research Study (HERS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Effect of race on insurance coverage and health service use for HIV-infected gay men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Translating clinical trial results into practice: the effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Factors associated with HIV-infected patients' recognition and use of HIV medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Protease inhibitor use among a community sample of people with HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Use of protease inhibitors among persons with AIDS in Los Angeles County

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Housing status and health care service utilization among low-income persons with HIV/AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Therapy naivete in the era of potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

The association of perceived health, clinical status, and initiation of HAART (highly active antiretroviral therapy) in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Determinants of antimicrobial prophylaxis use and treatment for wasting among patients with advanced human immunodeficiency virus disease in the United States, 1995-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Latina and African American women: continuing disparities in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Distinguishing efficacy, individual effectiveness and population effectiveness of therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

7 January 2021

Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

7 January 2021

Changes in insurance status and access to care for persons with AIDS in the Boston Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

7 January 2021

The association between primary source of ambulatory care and access to and outcomes of treatment among AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

7 January 2021

Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

7 January 2021

Use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors among Medicaid beneficiaries with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3549%2804%2950158-9

7 January 2021

10.1016/S0033-3549(04)50158-9

Identifiers

DOI

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

PubMed ID

12432135